Sigma-Aldrich Buys Stake in Sangamo, Will Co-Develop, Sell ZFP Research Reagents | GenomeWeb
NEW YORK (GenomeWeb News) — Sigma-Aldrich has made a $7.8 million equity investment in Sangamo BioSciences as part of the companies’ plan to co-develop and market zinc finger-based research reagents, the firms said yesterday.
The companies will use Sangamo’s ZFP technology to develop the reagents for a variety of cell analysis applications including cell lines with enhanced protein production performance, panels of knock-out cell lines for drug discovery, and stem cell and transgenic animal models.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.